The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Nomonde Ngema, 21, who was born with HIV, not only tackles the stigma on TikTok by sharing her journey, she also takes on ...

根据在2024年IDWeek上展示的研究结果，ibalizumab更频繁地被选用于晚期HIV患者，大多数受试者保持治疗超过两年，显示出持久性。该研究旨在为这组经常面临多重耐药问题的患者群体提供长期临床结果和影响病毒学控制的因素的见解。